Indo-Bangla Pharmaceuticals Limited (DSE:IBP)

Bangladesh flag Bangladesh · Delayed Price · Currency is BDT
14.10
+0.10 (0.71%)
At close: Feb 26, 2026
33.02%
Market Cap 1.64B
Revenue (ttm) 198.02M
Net Income (ttm) -32.60M
Shares Out 116.21M
EPS (ttm) -0.27
PE Ratio n/a
Forward PE n/a
Dividend 0.02 (0.11%)
Ex-Dividend Date Dec 8, 2025
Volume 2,058,417
Average Volume 1,729,523
Open 14.10
Previous Close 14.00
Day's Range 14.00 - 14.30
52-Week Range 8.50 - 15.60
Beta 0.09
RSI 70.58
Earnings Date Apr 30, 2026

About DSE:IBP

Indo-Bangla Pharmaceuticals Limited engages in the manufacture and sale of various medicines, medical preparations drugs, and chemicals in Bangladesh and internationally. The company’s principal products include Omeprazole, Esomeprazole, Dexamethasone, Domperidone, Metronidazole, Montelukast, Paracetamol, Sildenafil Citrate, and several other formulations. It markets its products in various forms, such as tablets, capsules. Indo-Bangla Pharmaceuticals Limited was founded in 1954 and is based in Dhaka, Bangladesh. [Read more]

Industry Pharmaceutical Preparations
Founded 1954
Employees 127
Stock Exchange Dhaka Stock Exchange
Ticker Symbol IBP
Full Company Profile

Financial Performance

In fiscal year 2025, DSE:IBP's revenue was 184.18 million, an increase of 4.27% compared to the previous year's 176.64 million. Losses were -36.83 million, -10.12% less than in 2024.

Financial Statements

News

There is no news available yet.